Key result
Laroprovstat 30 mg reduces LDL-C by ~51% after rosuvastatin run-in in patients with hypercholesterolemia.
Why the study?
Current PCSK9 inhibitors are injectable therapies, and no oral small-molecule PCSK9 inhibitor has yet been approved.
Does laroprovstat reduce LDL-C levels in treatment-naive patients with hypercholesterolemia?
Population
Healthy participants with LDL-C 70-190 mg/dL and participants with LDL-C 100-190 mg/dL
Comparison
Laroprovstat (1 mg or 30 mg) vs placebo once daily after rosuvastatin run-in
Design
Randomized, single-blind, placebo-controlled phase 1 trial
Follow-up
28 days
Authors
Loading...
Supports adding laroprovstat to rosuvastatin for further LDL-C lowering; extends evidence for oral PCSK9 inhibition in hypercholesterolemia.
RCT
Single-blind
Randomized
Does laroprovstat reduce LDL-C levels in treatment-naive patients with hypercholesterolemia?
Effect estimate: 51% reduction (95% CI 58%-44%)
Laroprovstat, a novel oral small-molecule PCSK9 inhibitor, significantly reduced LDL-C levels by up to 51% when added to rosuvastatin in treatment-naive patients with hypercholesterolemia, with no safety concerns.
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Vega et al. (2026) conducted an RCT in Hypercholesterolemia. Laroprovstat vs. Placebo was evaluated on Reduction in LDL-C compared with baseline (51% reduction, 95% CI 58%-44%). Laroprovstat 30 mg once daily reduced LDL-C by 51% (95% CI, 58%-44%) from baseline after a rosuvastatin run-in, achieving an 80% total reduction in patients with hypercholesterolemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: